Ubs Global Asset Management Americas »

Summit Therapeutics shares owned by Ubs Global Asset Management Americas

Quarter-by-quarter ownership of Summit Therapeutics (SMMT) shares owned by Ubs Global Asset Management Americas from 13F filings

Historical chart of Ubs Global Asset Management Americas investment in Summit Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Summit Therapeutics held by Ubs Global Asset Management Americas consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Summit Therapeutics by Ubs Global Asset Management Americas

Quarter filed Position value Share count Share price at filing
2024-03-31 $474k 115k 4.14
2023-12-31 $151k 58k 2.61
2023-09-30 $108k 58k 1.87

More positions owned by Ubs Global Asset Management Americas

Microsoft Corp Equity Us Cm (MSFT)
Apple Equity Us Cm (AAPL)
Nvidia Corp Equity Us Cm (NVDA)
Amazon Equity Us Cm (AMZN)
Alphabet Inc Cl A Equity Us Cm (GOOGL)
Meta Platforms Equity Us Cm (META)
Ishares Core Msci Eafe Equity (IEFA)
Alphabet Inc Cl C Equity Us Cm (GOOG)
Eli Lilly &#38 Equity Us Cm (LLY)
Broadcom Equity Us Cm (AVGO)
Tesla Equity Us Cm (TSLA)
Unitedhealth Group Equity Us Cm (UNH)
Advanced Micro Devices Equity Us Cm (AMD)
Visa Inc Class A Shares Equity Us Cm (V)
Jpmorgan Chase &#38 Company Equity Us Cm (JPM)

View all positions for Ubs Global Asset Management Americas

Top funds holding Summit Therapeutics

BlackRock
FMR
Vanguard Group
Geode Capital Management
Northern Trust
Charles Schwab Investment Management
Morgan Stanley
Goldman Sachs Group
Rafferty Asset Management
Steward Partners Investment Advisory
Bank Of Montreal
Citigroup
ALPS Advisors
UBS Group
Barclays

View all funds holding Summit Therapeutics